Improved therapy regimen employing first-, second-, and third-generation tyrosine kinase inhibitors (TKI) directed at the abnormal BCR-ABL1 fusion tyrosine kinase (TK) lead to achievements of durable cytogenetic (CyR) and molecular remissions (MR) in patients with chronic myeloid leukemia (CML). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.